Alpharma's Embeda has improved abuse profile, US panel says
This article was originally published in Scrip
Executive Summary
Alpharma's Embeda (ALO-01), a modified-release formulation of morphine coupled with the opioid antagonist naltrexone, is an incremental improvement over existing morphine products because it appears to be less susceptible to abuse and misuse, the FDA's anaesthetic and life support drugs and drug safety/risk management advisory panels said on November 14th.
You may also be interested in...
Puberty Blockers: FDA's Califf Asked If REMS, Boxed Warning Against Off-Label Use In The Works
FDA Commissioner Robert Califf tells House appropriations subcommittee chair the agency will 'consider any information that may be available' on off-label use of puberty blockers for gender dysphoria before making a regulatory decision.
ADHD Drugs: FDA Commissioner Blames Inappropriate Prescribing For Shortages
ADHD drug shortages may have resulted from industry reticence to fill DEA quotas, as well as a 'heavy element of professional responsibility' with off-label prescribing, Robert Califf told a House appropriations subcommittee.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.